Key Points Medical Properties Trust encountered severe problems in recent years. However, the REIT has made significant progress in putting those issues behind it. Its stock's juicy yield looks pretty safe. The past three years have been a roller-coaster ride for Medical Properties Trust(NYSE: MPW), a healthcare-focused real estate investment trust (REIT). The company encountered significant headwinds that negatively affected its financial results and stock price. However, MPT has made considerable headway in putting those issues behind it. As things stand, the stock's 6% yield looks relatively safe, at least for investors willing to stay the course. Here's why. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » No more dividend cuts on the horizon Income-focused investors often view REITs as stable options because of the regular, predictable rental income they receive from tenant companies. However, REITs are only as safe as the businesses they lease to. When some of their tenants suffer financially, they do too. That's what happened to MPT. Over the past three years, two of its tenants -- including its (now) former largest -- filed for bankruptcy. MPT's rentals and funds from operations (FFO) dropped. The company had no choice but to cut its dividend. MPW Revenue (Quarterly) data by YCharts. Income seekers don't like to see a payout cut, but it was a necessary evil for MPT to improve its business. Facing the loss of its largest tenant and substantial financial troubles, the company managed to craft a comeback plan. It sold some properties to raise money while finding new tenants for others that were previously occupied by its former tenants, who had declared bankruptcy. MPT also strengthened its balance sheet and improved its financial flexibility. It used the proceeds from the sale of various facilities and other sources to pay down significant amounts of debt, totaling $2.2 billion since the beginning of 2023. The company addressed all debt maturities through 2026, and also refinanced existing debt. All these transactions give MPT a much stronger financial foundation. That's not to mention the fact that, by putting several new tenants in old facilities, it has significantly diversified its operations; it's now far less susceptible to serious financial trouble because of the shortcomings of just one or two tenants. MPT still isn't getting the full rental revenue from its newest tenants. They'll gradually increase the amount they pay until they match 100% of the agreed terms by the fourth quarter of next year. In other words, it will still take some time for revenue and FFO to improve significantly. But I don't foresee the company encountering more serious issues and having to cut its dividend again. Story Continues There might be plenty of upside left MPT's shares have crushed the market this year; they're up by 45% year to date. There are several reasons for that. First, the stock was so beaten down that it had become undervalued, and opportunistic investors pounced despite the broader issues affecting equities. Second, dividend payers are exactly what investors look for in a challenging economic environment. Third, MPT is a REIT focusing on healthcare, a sector that will remain in high demand even if inflation or a recession hits because of the impact of tariffs. MPT has encountered severe issues in recent years. However, it has taken steps to get back on track, and investors now have a much improved outlook on the company. That said, its shares are still down over the past three years. Even after the recent rally, the stock has lost a whopping 70% of its value: MPW data by YCharts. True, MPT's turnaround isn't exactly complete, and there's still some risk involved. Unforeseen company-specific troubles could disrupt its plan -- recovering companies have very little margin for error. Also, the current economic situation could evolve in completely unpredictable ways. Even so, MPT's work to get past its issues over the past three years, and the fact that its share price is still down significantly, make it a stock worth considering. I wouldn't bet the farm on the stock, but it might be worth it for income seekers to initiate a small position and progressively add more shares if the company continues to improve. Should you invest $1,000 in Medical Properties Trust right now? Before you buy stock in Medical Properties Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medical Properties Trust wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $623,685!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $701,781!* Now, it’s worth notingStock Advisor’s total average return is906% — a market-crushing outperformance compared to164%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor. See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Dividend Stock Yielding 6% to Buy and Hold was originally published by The Motley Fool View Comments
1 Dividend Stock Yielding 6% to Buy and Hold
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...